BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 3.62 (+0.16)
Ardelyx (ARDX) Catches Eye: Stock Moves 14.2% Higher
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 7:25AM CDT
Ardelyx, Inc. (ARDX) moved big last session, as its shares jumped over 14% on the day.
ARDX: 10.68 (+0.06)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 22.30 (-0.83), UTHR: 121.01 (+2.02), AZN: 34.14 (-0.15)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 8.35 (-0.12)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), PFE: 36.89 (+0.22), AMGN: 172.03 (+0.75), ABBV: 66.23 (+1.51), RDY: 43.65 (+0.04), AVXS: 37.63 (+0.13), NVS: 83.26 (+1.18)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 31.42 (-0.05), CLSN: 1.23 (unch), JAZZ: 150.97 (-1.85)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 9.94 (+0.17), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 8.28 (+0.01), BXLT: 46.02 (-0.18), ARNA: 1.67 (-0.01)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 8.28 (+0.01), BXLT: 46.02 (-0.18), ARNA: 1.67 (-0.01)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 150.97 (-1.85), TEVA: 53.50 (-1.29), CNCE: 11.49 (-0.28)
Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 10:35AM CDT
Corcept Therapeutics (CORT) posted loss of a penny per share in the second quarter of 2015, narrower than both the Zacks Consensus Estimate of a loss of 5 cents.
VRX: 22.30 (-0.83), ANAC: 99.06 (-0.14), CORT: 5.80 (-0.06)
Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 8:10AM CDT
Although Arena Pharmaceuticals' (ARNA) second quarter loss was narrower-than-expected, revenues missed expectations.
GILD: 79.47 (-1.77), ARNA: 1.67 (-0.01)
Will Epizyme (EPZM) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 12:40PM CDT
Epizyme (EPZM) has an Earnings ESP of 3.08% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
INO: 9.88 (+0.26), EPZM: 10.36 (+0.10), GSK: 45.07 (-0.11)
Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 12:00PM CDT
Investor focus will remain on the performance of Arena's (ARNA) obesity treatment - Belviq.
BDSI: 2.55 (+0.20), VVUS: 1.07 (+0.01), ARNA: 1.67 (-0.01)